Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage
<b>Background/Objectives</b>: Triple-negative breast cancer (TNBC) is a heterogeneous entity lacking ER, PR, and HER2, with aggressive biology and high recurrence risk. Neoadjuvant chemotherapy (NACT) is the standard of care, and a pathological complete response (pCR) is a surrogate marker for survival. Within TNBC, apocrine differentiation (TNAC) is a distinct subtype, often androgen receptor (AR)-positive, with lower chemosensitivity but a favorable prognosis. Comparative studies of TNAC versus classical TNBC remain limited. This study aimed to define clinical and biological differences between TNAC and non-apocrine TNBC (NA-TNBC), representing the largest TNAC cohort to date. <b>Methods</b>: This retrospective study included 129 non-metastatic TNBC patients treated with NACT and surgery (2010-2020). Patients were classified as TNAC or NA-TNBC. Demographic, clinicopathological, and immunohistochemical data (including Ki-67 and AR) were collected. Tumor-infiltrating lymphocytes (TILs), delta Ki-67, pathological complete response (pCR), and survival outcomes were evaluated. <b>Results</b>: Of 129 TNBC patients, 45 (34.9%) were TNAC. AR positivity occurred in 64.4% of TNACs. TNAC patients were predominantly postmenopausal. pCR rates were significantly lower in TNAC (6.6% vs. 30.9%, <i>p</i> = 0.002). TNACs exhibited lower baseline Ki-67, delta Ki-67, and TIL positivity (13.3% vs. 30%). Despite this, 5-year overall survival was higher in TNAC (86% vs. 78%). Delta Ki-67 > 20% strongly predicted pCR across the cohort (<i>p</i> < 0.001). Carboplatin was rarely used in TNAC (8.3%), but was associated with a higher pCR rate (50% vs. 2.4%, <i>p</i> = 0.018). <b>Conclusions</b>: TNAC represents a biologically distinct TNBC subtype, characterized by low pCR but favorable survival. Recognition of its unique features may guide treatment de-escalation and exploration of AR-targeted therapies. Prospective studies focusing on TNAC are warranted.
Authors
- Sıla Öksüz (ORCID: https://orcid.org/0000-0003-4721-0585)
- Heves Sürmeli (ORCID: https://orcid.org/0000-0003-1604-8466)
- Özlem Nuray Sever (ORCID: https://orcid.org/0000-0003-3462-9360)
- Oğuzcan Kınıkoğlu (ORCID: https://orcid.org/0000-0001-5983-3291)
- Nedim Turan (ORCID: https://orcid.org/0000-0002-1140-8779)
- Tuğba Başoğlu (ORCID: https://orcid.org/0000-0002-2059-5502)
- Şermin Çoban Kökten (ORCID: https://orcid.org/0000-0003-1780-2942)
- Sedat Yıldırım (ORCID: https://orcid.org/0000-0002-2423-6902)
- Uğur Özkerim (ORCID: https://orcid.org/0000-0001-8527-1392)
- Hatice Odabaş (ORCID: https://orcid.org/0000-0002-5757-4705)
- Deniz Işık (ORCID: https://orcid.org/0000-0003-4398-5148)
- Seval Ay (ORCID: https://orcid.org/0000-0002-7555-2657)
Institutions
- Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3390/jcm14197103
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00